ALM Stock Overview
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Almirall, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.86 |
| 52 Week High | €10.08 |
| 52 Week Low | €7.16 |
| Beta | 0.38 |
| 1 Month Change | 6.31% |
| 3 Month Change | 23.81% |
| 1 Year Change | 22.19% |
| 3 Year Change | -32.13% |
| 5 Year Change | -36.46% |
| Change since IPO | -34.30% |
Recent News & Updates
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
Apr 24
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Mar 20Recent updates
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
Apr 24These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Mar 20Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Dec 15Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?
Oct 03We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Aug 24Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?
Jul 05Is Almirall (BME:ALM) A Risky Investment?
May 16Estimating The Fair Value Of Almirall, S.A. (BME:ALM)
Mar 29We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Jan 04An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued
Dec 01Almirall (BME:ALM) Seems To Use Debt Quite Sensibly
Jul 14Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Mar 23Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price
Feb 24Is Almirall (BME:ALM) Using Too Much Debt?
Nov 01Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price
Aug 02Is Almirall (BME:ALM) Using Too Much Debt?
Jul 06Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden
Mar 23How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?
Mar 05Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate
Feb 15Almirall, S.A. (BME:ALM) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Feb 02Would Shareholders Who Purchased Almirall's (BME:ALM) Stock Five Years Be Happy With The Share price Today?
Jan 20Shareholder Returns
| ALM | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | 2.9% | 0.03% | -3.1% |
| 1Y | 22.2% | 18.5% | 13.8% |
Return vs Industry: ALM exceeded the Spanish Pharmaceuticals industry which returned 18.5% over the past year.
Return vs Market: ALM exceeded the Spanish Market which returned 13.8% over the past year.
Price Volatility
| ALM volatility | |
|---|---|
| ALM Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in ES Market | 6.5% |
| 10% least volatile stocks in ES Market | 1.0% |
Stable Share Price: ALM has not had significant price volatility in the past 3 months.
Volatility Over Time: ALM's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 1,904 | Carlos Gallardo Piqué | www.almirall.com |
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.
Almirall, S.A. Fundamentals Summary
| ALM fundamental statistics | |
|---|---|
| Market cap | €2.06b |
| Earnings (TTM) | -€38.77m |
| Revenue (TTM) | €915.09m |
2.3x
P/S Ratio-53.2x
P/E RatioIs ALM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALM income statement (TTM) | |
|---|---|
| Revenue | €915.09m |
| Cost of Revenue | €245.20m |
| Gross Profit | €669.89m |
| Other Expenses | €708.66m |
| Earnings | -€38.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 22, 2024
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 73.21% |
| Net Profit Margin | -4.24% |
| Debt/Equity Ratio | 23.9% |
How did ALM perform over the long term?
See historical performance and comparison